Literature DB >> 19843846

Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality.

Lara S Collier1, David J Adams, Christopher S Hackett, Laura E Bendzick, Keiko Akagi, Michael N Davies, Miechaleen D Diers, Fausto J Rodriguez, Aaron M Bender, Christina Tieu, Ilze Matise, Adam J Dupuy, Neal G Copeland, Nancy A Jenkins, J Graeme Hodgson, William A Weiss, Robert B Jenkins, David A Largaespada.   

Abstract

The Sleeping Beauty (SB) transposon system has been used as a somatic mutagen to identify candidate cancer genes. In previous studies, efficient leukemia/lymphoma formation on an otherwise wild-type genetic background occurred in mice undergoing whole-body mobilization of transposons, but was accompanied by high levels of embryonic lethality. To explore the utility of SB for large-scale cancer gene discovery projects, we have generated mice that carry combinations of different transposon and transposase transgenes. We have identified a transposon/transposase combination that promotes highly penetrant leukemia/lymphoma formation on an otherwise wild-type genetic background, yet does not cause embryonic lethality. Infiltrating gliomas also occurred at lower penetrance in these mice. SB-induced or accelerated tumors do not harbor large numbers of chromosomal amplifications or deletions, indicating that transposon mobilization likely promotes tumor formation by insertional mutagenesis of cancer genes, and not by promoting wide-scale genomic instability. Cloning of transposon insertions from lymphomas/leukemias identified common insertion sites at known and candidate novel cancer genes. These data indicate that a high mutagenesis rate can be achieved using SB without high levels of embryonic lethality or genomic instability. Furthermore, the SB system could be used to identify new genes involved in lymphomagenesis/leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843846      PMCID: PMC2771123          DOI: 10.1158/0008-5472.CAN-09-1760

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Target-site preferences of Sleeping Beauty transposons.

Authors:  Geyi Liu; Aron M Geurts; Kojiro Yae; A R Srinivasan; Scott C Fahrenkrug; David A Largaespada; Junji Takeda; Kyoji Horie; Wilma K Olson; Perry B Hackett
Journal:  J Mol Biol       Date:  2004-12-30       Impact factor: 5.469

Review 2.  Transforming science: cancer gene identification.

Authors:  Lara S Collier; David A Largaespada
Journal:  Curr Opin Genet Dev       Date:  2005-12-01       Impact factor: 5.578

3.  Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells.

Authors:  Z Ivics; P B Hackett; R H Plasterk; Z Izsvák
Journal:  Cell       Date:  1997-11-14       Impact factor: 41.582

4.  Transposition and gene disruption in the male germline of the mouse.

Authors:  A J Dupuy; S Fritz; D A Largaespada
Journal:  Genesis       Date:  2001-06       Impact factor: 2.487

5.  RTCGD: retroviral tagged cancer gene database.

Authors:  Keiko Akagi; Takeshi Suzuki; Robert M Stephens; Nancy A Jenkins; Neal G Copeland
Journal:  Nucleic Acids Res       Date:  2004-01-01       Impact factor: 16.971

6.  Chromosomal transposition of a Tc1/mariner-like element in mouse embryonic stem cells.

Authors:  G Luo; Z Ivics; Z Izsvák; A Bradley
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

7.  E1A signaling to p53 involves the p19(ARF) tumor suppressor.

Authors:  E de Stanchina; M E McCurrach; F Zindy; S Y Shieh; G Ferbeyre; A V Samuelson; C Prives; M F Roussel; C J Sherr; S W Lowe
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

8.  Vav promoter-tTA conditional transgene expression system for hematopoietic cells drives high level expression in developing B and T cells.

Authors:  Won-Il Kim; Stephen M Wiesner; David A Largaespada
Journal:  Exp Hematol       Date:  2007-06-07       Impact factor: 3.084

9.  High-throughput retroviral tagging to identify components of specific signaling pathways in cancer.

Authors:  Harald Mikkers; John Allen; Puck Knipscheer; Like Romeijn; Augustinus Hart; Edwin Vink; Anton Berns; Lieke Romeyn
Journal:  Nat Genet       Date:  2002-08-19       Impact factor: 38.330

10.  Harnessing a high cargo-capacity transposon for genetic applications in vertebrates.

Authors:  Darius Balciunas; Kirk J Wangensteen; Andrew Wilber; Jason Bell; Aron Geurts; Sridhar Sivasubbu; Xin Wang; Perry B Hackett; David A Largaespada; R Scott McIvor; Stephen C Ekker
Journal:  PLoS Genet       Date:  2006-08-28       Impact factor: 5.917

View more
  41 in total

Review 1.  Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions.

Authors:  Jon D Larson; David A Largaespada
Journal:  In Vivo       Date:  2012 Jul-Aug       Impact factor: 2.155

2.  Establishment of a pig fibroblast-derived cell line for locus-directed transgene expression in cell cultures and blastocysts.

Authors:  Jannik E Jakobsen; Juan Li; Brian Moldt; Peter M Kragh; Henrik Callesen; Jens Michael Hertz; Lars Bolund; Arne Lund Jørgensen; Jacob Giehm Mikkelsen; Anders Lade Nielsen
Journal:  Mol Biol Rep       Date:  2010-03-25       Impact factor: 2.316

Review 3.  Transposon-based screens for cancer gene discovery in mouse models.

Authors:  Adam J Dupuy
Journal:  Semin Cancer Biol       Date:  2010-05-15       Impact factor: 15.707

Review 4.  In vivo functional screening for systems-level integrative cancer genomics.

Authors:  Julia Weber; Christian J Braun; Dieter Saur; Roland Rad
Journal:  Nat Rev Cancer       Date:  2020-07-07       Impact factor: 60.716

5.  Insertional mutagenesis using the Sleeping Beauty transposon system identifies drivers of erythroleukemia in mice.

Authors:  Keith R Loeb; Bridget T Hughes; Brian M Fissel; Nyka J Osteen; Sue E Knoblaugh; Jonathan E Grim; Luke J Drury; Aaron Sarver; Adam J Dupuy; Bruce E Clurman
Journal:  Sci Rep       Date:  2019-04-02       Impact factor: 4.379

6.  Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas.

Authors:  Aaron M Bender; Lara S Collier; Fausto J Rodriguez; Christina Tieu; Jon D Larson; Chandralekha Halder; Eric Mahlum; Thomas M Kollmeyer; Keiko Akagi; Gobinda Sarkar; David A Largaespada; Robert B Jenkins
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

Review 7.  Genetically engineered mouse models in cancer research.

Authors:  Jessica C Walrath; Jessica J Hawes; Terry Van Dyke; Karlyne M Reilly
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

8.  Cell of origin strongly influences genetic selection in a mouse model of T-ALL.

Authors:  Katherine E Berquam-Vrieze; Kishore Nannapaneni; Benjamin T Brett; Linda Holmfeldt; Jing Ma; Oksana Zagorodna; Nancy A Jenkins; Neal G Copeland; David K Meyerholz; C Michael Knudson; Charles G Mullighan; Todd E Scheetz; Adam J Dupuy
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

Review 9.  Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy.

Authors:  Perry B Hackett; David A Largaespada; Kirsten C Switzer; Laurence J N Cooper
Journal:  Transl Res       Date:  2013-01-10       Impact factor: 7.012

10.  Adaptive immunity does not strongly suppress spontaneous tumors in a Sleeping Beauty model of cancer.

Authors:  Laura M Rogers; Alicia K Olivier; David K Meyerholz; Adam J Dupuy
Journal:  J Immunol       Date:  2013-03-08       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.